Clinical Trial Update: A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intermittent treatment with ulipristal acetate for abnormal uterine bleeding due to leiomyomas has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyoma
• Uterine Hemorrhage

Drugs mentioned

• Ulipristal acetate (ulipristal acetate)

Snippet

Sponsor: Allergan | Conditions: Leiomyoma, Uterine Hemorrhage | Phase 3 | Status: COMPLETED | Results posted: 2019-06-04